Atypical Hemolytic Uremic Syndrome Clinical Trials in Bordeaux
2 recruitingBordeaux, France
Showing 1–2 of 2 trials
Recruiting
Phase 3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Atypical Hemolytic Uremic Syndrome
Alexion Pharmaceuticals, Inc.3,000 enrolled141 locationsNCT01522183